disodium;[(2R,3S,4R,5R)-3,4-dihydroxy-5-(4-oxido-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl hydrogen phosphate

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘧啶核苷酸
• 英文名称: disodium;[(2R,3S,4R,5R)-3,4-dihydroxy-5-(4-oxido-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl hydrogen phosphate
• 化学式: C9H11N2Na2O9P
• 分子量: 368.14
• InChiKey: KURVIXMFFSNONZ-WFIJOQBCSA-L

计算性质

• 辛醇/水分配系数(LogP)：
  -9.99
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  172
• 氢给体数：
  3
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  disodium;[(2R,3S,4R,5R)-3,4-dihydroxy-5-(4-oxido-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl hydrogen phosphate 、 三乙基铵阳离子 以 水 为溶剂， 以was obtained (0.78 g, 80%)的产率得到Triethylammonium uridine 5'-phosphate
  参考文献：
  名称：

  LABELING AND DETECTION OF POST TRANSLATIONALLY MODIFIED PROTEINS

  摘要：

  在某些实施例中，提供了一种形成含偶氮基改性生物分子共轭物的报告分子、载体分子或固体支持的新方法。在其他实施例中，提供了一种用酶标记含偶氮基的生物分子的方法。

  公开号：

  US20150051096A1

文献信息

• [EN] COMPOUNDS USEFUL FOR THE TREATMENT AND/OR CARE OF THE SKIN, HAIR, NAILS AND/OR MUCOUS MEMBRANES<br/>[FR] COMPOSÉS UTILES DANS LE TRAITEMENT ET/OU LES SOINS DE LA PEAU, DES CHEVEUX, DES ONGLES ET/OU DES MEMBRANES MUQUEUSES
  申请人：LUBRIZOL ADVANCED MATERIALS INC

  公开号：WO2020161683A1

  公开（公告）日：2020-08-13

  The invention relates to a compound of formula (I) R1 - Wm-Xn-AAi - AA2-AA3-AA4-AA5-AA6- Yp-Zq-Ra, a stereoisomer and/or cosmetically acceptable salt thereof wherein: AA1 is Asp, Gly, Asn, Gln, Ala or no amino acid; AA2 is Val, Ile, Leu or Ala; AA3 is Tyr, Phe, Trp, Lys, Arg or His; AA4 is Lys, Arg, His, Pro or Val; AA5 is Asn, Asp, Gln or no amino acid; AA6 is Thr, Ala, Ser or no amino acid. The compounds are useful for the treatment and/or prevention of the symptoms of skin aging and, in particular, for the treatment and/or prevention of skin wrinkles, the treatment and/or prevention of a sagging appearance of the skin, and/or the reduction and/or prevention of facial asymmetry.

  该发明涉及一种化合物，其化学式为（I）R1 - Wm-Xn-AAi - AA2-AA3-AA4-AA5-AA6- Yp-Zq-Ra，以及其立体异构体和/或在化妆品中可接受的盐，其中：AA1为Asp、Gly、Asn、Gln、Ala或无氨基酸；AA2为Val、Ile、Leu或Ala；AA3为Tyr、Phe、Trp、Lys、Arg或His；AA4为Lys、Arg、His、Pro或Val；AA5为Asn、Asp、Gln或无氨基酸；AA6为Thr、Ala、Ser或无氨基酸。这些化合物可用于治疗和/或预防皮肤衰老症状，特别是用于治疗和/或预防皮肤皱纹，治疗和/或预防皮肤松弛外观，以及/或减少和/或预防面部不对称。
• [EN] PROCESS FOR THE CYCLOADDITION OF A HALOGENATED 1,3-DIPOLE COMPOUND WITH A (HETERO)CYCLOALKYNE<br/>[FR] PROCÉDÉ DE CYCLOADDITION D'UN COMPOSÉ 1,3-DIPPOLE HALOGÉNÉ AVEC UN (HÉTÉRO)CYCLOALKYNE
  申请人：SYNAFFIX BV

  公开号：WO2015112016A1

  公开（公告）日：2015-07-30

  The present invention relates to a cycloaddition process comprising the step of reacting a halogenated aliphatic 1,3-dipole compound with a (hetero)cycloalkyne according to Formula (1): Preferably, the (hetero)cycloalkyne according to Formula (1) is a (hetero)cyclooctyne. The invention also relates to the cycloaddition products obtainable by the process according to the invention. The invention further relates to halogenated aliphatic 1,3- dipole compounds, in particular tohalogenated aliphatic 1,3-dipole compounds comprising N-acetylgalactosamine-UDP (GalNAc-UDP),and to halogenated 1,3- dipole compounds comprising (peracylated) N-acetylglucosamine(GlcNAc), N- acetylgalactosamine(GalNAc), N-acetylmannosamine(ManNAc)and N- acetylneuraminic acid(NeuNAc).

  本发明涉及一种环加成过程，包括将卤代脂肪1,3-二极化合物与按照式（1）反应的（杂）环烯烃化合物进行反应的步骤。优选，按照式（1）的（杂）环烯烃化合物是（杂）环辛烯。该发明还涉及根据本发明的方法获得的环加成产物。此外，该发明还涉及卤代脂肪1,3-二极化合物，特别是包括N-乙酰半乳糖氨基葡萄糖醛酸-UDP（GalNAc-UDP）的卤代脂肪1,3-二极化合物，以及包括（过酰化的）N-乙酰葡萄糖胺（GlcNAc）、N-乙酰半乳糖氨基葡萄糖醛酸（GalNAc）、N-乙酰甘露糖氨基葡萄糖醛酸（ManNAc）和N-乙酰神经酸（NeuNAc）的卤代1,3-二极化合物。
• [EN] COMPOUNDS USEFUL IN THE TREATMENT AND/OR CARE OF THE SKIN, HAIR, NAILS, AND/OR MUCOUS MEMBRANES<br/>[FR] COMPOSÉS UTILES DANS LE TRAITEMENT ET/OU LE SOIN DE LA PEAU, DES CHEVEUX, DES ONGLES ET/OU DES MEMBRANES MUQUEUSES
  申请人：LUBRIZOL ADVANCED MAT INC

  公开号：WO2017100421A1

  公开（公告）日：2017-06-15

  Compounds of general formula (I): R1-Wm-Xn-AA1-AA2-AA3-AA4-AA5-AA6-Yp-Zq-R2 (I) their stereoisomers, mixtures thereof and/or their cosmetically or pharmaceutically acceptable salts, cosmetic and/or pharmaceutical compositions which contain them and their use in medicine, and in processes of treatment and/or care of the skin, hair and/or mucous membranes, in particular in the aging and photoaging of the skin.

  通式（I）的化合物：R1-Wm-Xn-AA1-AA2-AA3-AA4-AA5-AA6-Yp-Zq-R2（I），它们的立体异构体、混合物和/或其在化妆品或药用上可接受的盐，含有它们的化妆品和/或药用组合物，以及它们在医学中的使用，以及在皮肤、头发和/或黏膜的治疗和/或护理过程中的使用，特别是在皮肤的衰老和光老化方面。
• [EN] SULFAMIDE LINKER, CONJUGATES THEREOF, AND METHODS OF PREPARATION<br/>[FR] LIEUR DE TYPE SULFAMIDE, CONJUGUÉS DE CELUI-CI ET PROCÉDÉS DE PRÉPARATION
  申请人：SYNAFFIX BV

  公开号：WO2016053107A1

  公开（公告）日：2016-04-07

  The present invention relates to a compound comprising an alpha-end and an omega-end, the compound comprising on the alpha-end a reactive group Qlcapable of reacting with a functional group F1present on a biomolecule and on the omega-end a target molecule, the compound further comprising a group according to formula (1) or a salt thereof: Said compound may also be referred to as a linker-conjugate. The invention also relates to a process for the preparation of a bioconjugate, the process comprising the step of reacting a reactive group Q1of a linker-conjugate according to the invention with a functional group F1of a biomolecule. The invention further relates to a bioconjugate obtainable by the process according to the invention. In a preferred embodiment, the invention concerns a process for the preparation of a bioconjugate via a cycloaddition, such as a (4+2)-cycloaddition (e.g. a Diels-Alder reaction) or a (3+2)-cycloaddition (e.g. a 1,3-dipolar cycloaddition).

  本发明涉及一种化合物，包括一个α端和一个ω端，该化合物在α端包括一个与生物分子上存在的功能基团F1反应的反应基团Q1，而在ω端包括一个靶分子，该化合物还包括符合以下式（1）或其盐的一个基团：该化合物也可以称为连接物-共轭物。本发明还涉及一种制备生物共轭物的方法，该方法包括将本发明中连接物-共轭物的反应基团Q1与生物分子的功能基团F1反应的步骤。本发明还涉及通过本发明方法获得的生物共轭物。在一个首选实施方式中，本发明涉及通过环加成反应制备生物共轭物的方法，例如（4+2）-环加成反应（例如Diels-Alder反应）或（3+2）-环加成反应（例如1,3-双极环加成）。
• METHOD FOR PRODUCING MONOMER FOR SINGLE-STRANDED NUCLEIC ACID MOLECULE
  申请人：SUMITOMO CHEMICAL COMPANY, LIMITED

  公开号：US20190100540A1

  公开（公告）日：2019-04-04

  A compound represented by formula (3): or an enantiomer thereof can be obtained by comprising: reacting a compound represented by formula (1): or an enantiomer thereof with 6-hydroxyhexanoic acid in a solvent in the presence of an additive such as 1-hydroxybenzotriazole and a condensing agent, and then mixing the resultant reaction mixture, water, and a base such as alkali metal hydroxide to produce a compound represented by formula (2): or an enantiomer thereof; and reacting the compound represented by formula (2) or an enantiomer thereof with 2-cyanoethyl-N,N,N′,N′-tetraisopropylphosphorodiamidite in a solvent in the presence of a coupling activator.

  通过在溶剂中添加1-羟基苯并三唑和缩合剂的存在，将由式（1）表示的化合物或其对映体与6-羟基己酸反应，然后混合产生的反应混合物、水和碱金属氢氧化物，可以获得由式（2）表示的化合物或其对映体；并且将由式（2）表示的化合物或其对映体与2-氰乙基-N，N，N'，N' -四异丙基膦酰胺在溶剂中反应，在偶联活化剂的存在下。

表征谱图